Estrogen patches face shortage as more women seek hormone therapy – PBS
Estrogen patch shortages affect women seeking hormone therapy as demand surges and supply chain struggles to keep pace.
Estrogen patch shortages affect women seeking hormone therapy as demand surges and supply chain struggles to keep pace.
The peptide craze reveals Americans’ willingness to embrace unproven treatments despite limited safety data and regulatory oversight.
UK medicines watchdog MHRA investigates peptide clinics over concerns about unsubstantiated health claims and marketing practices.
Novo Nordisk expands its obesity treatment lineup with a high-dose Wegovy formulation as competition in the GLP-1 market intensifies.
Indirect comparison reveals oral semaglutide produces greater weight loss than orforglipron in clinical trial analysis.
UK’s MHRA investigates peptide clinics over potentially misleading health claims and unlicensed medical products.
WFLA’s Bloom explores hormone replacement therapy options for women managing perimenopause and menopause symptoms.
Ohio’s refusal to cover obesity drugs like Ozempic for state employees draws criticism as shortsighted policy that ignores long-term savings.
Novo Nordisk’s oral Wegovy pill attracts weight loss patients who previously avoided injectable GLP-1 medications.
Inno Supps launches NMN+, targeting cellular aging with NAD+ precursor nicotinamide mononucleotide for longevity support.